Show simple item record

dc.contributor.authorHowell, Anthony
dc.date.accessioned2009-07-06T16:36:34Z
dc.date.available2009-07-06T16:36:34Z
dc.date.issued2006-03
dc.identifier.citationFulvestrant ('Faslodex'): current and future role in breast cancer management. 2006, 57 (3):265-73 Crit. Rev. Oncol. Hematol.en
dc.identifier.issn1040-8428
dc.identifier.pmid16473018
dc.identifier.doi10.1016/j.critrevonc.2005.08.001
dc.identifier.urihttp://hdl.handle.net/10541/72645
dc.description.abstractFulvestrant ('Faslodex') is a new type of estrogen receptor antagonist with no agonist effects, that reduces cellular levels of both estrogen and progesterone receptors. Results from two Phase III trials showed that fulvestrant is at least as effective as the third-generation selective aromatase inhibitor anastrozole in postmenopausal women with advanced breast cancer following progression on antiestrogen therapy, indicating the potential for second-line fulvestrant in this setting. In clinical practice, fulvestrant is well tolerated, with good rates of clinical benefit observed as first-line therapy and following progression on prior endocrine agents. Other endocrine agents have been shown to have good clinical activity when resistance to fulvestrant has developed, showing that fulvestrant lacks cross-resistance with other treatments. Ongoing trials are investigating the efficacy of fulvestrant after failure on aromatase inhibitors and evaluating its use in combination with therapies that target growth factor receptor signaling pathways.
dc.language.isoenen
dc.subjectBreast Canceren
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshAromatase
dc.subject.meshBreast Neoplasms
dc.subject.meshClinical Trials, Phase III as Topic
dc.subject.meshDrug Resistance, Neoplasm
dc.subject.meshEnzyme Inhibitors
dc.subject.meshEstradiol
dc.subject.meshEstrogen Antagonists
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshPostmenopause
dc.subject.meshReceptors, Estrogen
dc.subject.meshReceptors, Somatotropin
dc.subject.meshSignal Transduction
dc.titleFulvestrant ('Faslodex'): current and future role in breast cancer management.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, Withington, Manchester M20 4BX, UK. maria.parker@christie-tr.nwest.nhs.uken
dc.identifier.journalCritical Reviews in Oncology/Hematologyen
html.description.abstractFulvestrant ('Faslodex') is a new type of estrogen receptor antagonist with no agonist effects, that reduces cellular levels of both estrogen and progesterone receptors. Results from two Phase III trials showed that fulvestrant is at least as effective as the third-generation selective aromatase inhibitor anastrozole in postmenopausal women with advanced breast cancer following progression on antiestrogen therapy, indicating the potential for second-line fulvestrant in this setting. In clinical practice, fulvestrant is well tolerated, with good rates of clinical benefit observed as first-line therapy and following progression on prior endocrine agents. Other endocrine agents have been shown to have good clinical activity when resistance to fulvestrant has developed, showing that fulvestrant lacks cross-resistance with other treatments. Ongoing trials are investigating the efficacy of fulvestrant after failure on aromatase inhibitors and evaluating its use in combination with therapies that target growth factor receptor signaling pathways.


Files in this item

This item appears in the following Collection(s)

Show simple item record